Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Julissa Molina-Vega"'
Autor:
Harriet T. Rothschild, Elle Clelland, Anne Patterson, Julissa Molina-Vega, Mandeep Kaur, W. Fraser Symmans, Christopher J. Schwartz, A. Jo Chien, Rita A. Mukhtar
Publikováno v:
Breast cancer research and treatment, vol 199, iss 2
Purpose HER2 overexpression has a central role in breast cancer carcinogenesis and is associated with poor prognosis if untreated. Lately, identification of HER2-low breast cancer has been proposed to select patients for novel HER2-directed chemother
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74d1ab2ecaa48a3eb96f73da3475bedd
https://doi.org/10.1007/s10549-023-06927-x
https://doi.org/10.1007/s10549-023-06927-x
Autor:
Jennifer Rosenbluth, Christopher J. Schwartz, Tam Binh Bui, Shruti Warhadpande, Pravin Phadatare, Sigal Eini, Michael Bruck, Julissa Molina-Vega, Kami Pullakhandam, Nicole Schindler, Lamorna A. Brown Swigart, Christina Yau, Gillian Hirst, Rita Mukhtar, Karthik V. Giridhar, Olufunmilayo I. Olopade, Kevin Kalinsky, Cheryl A. Ewing, Jasmine M. Wong, Michael D. Alvarado, Laura Van’t Veer, Laura J. Esserman, Jo Chien
Publikováno v:
Cancer Research. 83:P3-09
Background: Treatment of estrogen receptor (ER)-positive breast cancer with selective estrogen receptor degraders (SERDs) frequently results in the loss or reduction of ER expression. Whether these changes are due to on-target effects of SERDs degrad
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::56b85e079ba7ad008def92702e3da5f8
https://doi.org/10.1158/1538-7445.sabcs22-p3-09-01
https://doi.org/10.1158/1538-7445.sabcs22-p3-09-01
Autor:
Amrita Basu, Saumya Umashankar, Kaylee Blevins, Anna Northrop, Anika Christofferson, Ebunoluwa Olunuga, Jaeyoon Cha, Ananya Mittal, Julissa Molina-Vega, Laura Sit, Thelma Brown, Bev Parker, Diane Heditsian, Susie Brain, Carol Simmons, Alessandra Taboada, Tina J. Hieken, Kathryn Ruddy, Carolina Salvador, Candace Mainor, Anosheh Afghahi, Sarah Tevis, Anne Blaes, Irene M. Kang, Jane Perlmutter, Hope Rugo, Sai Kanaparthi, Garry Peterson, Lisa T. Weiss, Adam Asare, Laura J. Esserman, Michelle Melisko, Dawn Hershman
Publikováno v:
Cancer Research. 83:P5-07
Background. Patient-reported outcomes (PROs) are increasingly recognized as a valuable component to understand treatment tolerability and toxicity among patients on clinical trials. We have implemented a system for monitoring patient reported outcome
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::83ceaa8ddecc389b4ebe1e9ddb64f749
https://doi.org/10.1158/1538-7445.sabcs22-p5-07-03
https://doi.org/10.1158/1538-7445.sabcs22-p5-07-03
Autor:
Mandeep Kaur, Anne Patterson, Julissa Molina-Vega, Harriet T. Rothschild, Elle Clelland, Mary Kathryn Abel, Laura J. Esserman, Olufunmilayo I. Olopade, Rita Mukhtar
Publikováno v:
Cancer Research. 83:P6-08
Objectives: Investigators have shown a relationship between race/ethnicity and survival in invasive lobular carcinoma (ILC), the second most common type of breast cancer. While non-white patients with ILC were shown to have worse outcomes, there are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1913cba69fb2b3f38034e8dacb721f73
https://doi.org/10.1158/1538-7445.sabcs22-p6-08-09
https://doi.org/10.1158/1538-7445.sabcs22-p6-08-09
Autor:
Kent Goodman, Mary Kathryn Abel, Courtney Lawhn-Heath, Julissa Molina-Vega, Ella F. Jones, Rita A. Mukhtar
Publikováno v:
Surgical Oncology Clinics of North America. 31:569-579
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0e2ae134233cbd35a690e5d443727077
https://doi.org/10.1016/j.soc.2022.06.001
https://doi.org/10.1016/j.soc.2022.06.001
Autor:
Mandeep Kaur, Anne Patterson, Julissa Molina-Vega, Harriet Rothschild, Elle Clelland, Cheryl A. Ewing, Firdows Mujir, Laura J. Esserman, Olufunmilayo I. Olopade, Rita A. Mukhtar
Publikováno v:
Cancer Epidemiology, Biomarkers & Prevention.
Background: While investigators have shown associations between socioeconomic status (SES) and outcomes in breast cancer, there is a paucity of such data for invasive lobular carcinoma (ILC), the second most common type of breast cancer. Herein we ev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4fd7f9aae1dea3687c1ce8767c65523a
https://doi.org/10.1158/1055-9965.epi-22-1353
https://doi.org/10.1158/1055-9965.epi-22-1353
Autor:
A. Jo Chien, Kevin M Kalinsky, Julissa Molina-Vega, Rita Mukhtar, Karthik Giridhar, Olufunmilayo I Olopade, Amrita Basu, Smita M Asare, Paul Henderson, Gillian Hirst, Ruixiao Lu, Ella Jones, Nola Hylton, Lamorna Brown-Swigart, Laura J van 't Veer, Douglas Yee, Ingrid Mayer, Laura J Esserman
Publikováno v:
Cancer Research. 82:OT1-10
Background: There is no clinical equipoise on the best upfront management of patients with early-stage hormone receptor-positive (HR+)/HER2-negative (HER2-) breast cancer (BC) that is high-risk by clinicopathologic criteria, and low-risk based on mol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::58a72e7aff74ff9a45915a92aa8f48e2
https://doi.org/10.1158/1538-7445.sabcs21-ot1-10-02
https://doi.org/10.1158/1538-7445.sabcs21-ot1-10-02
Autor:
Elle Clelland, Harriet T. Rothschild, Anne Patterson, Julissa Molina-Vega, Mandeep Kaur, Mary Kathryn Abel, W. Fraser Symmans, Jo Chien, Christopher J. Schwartz, Rita Mukhtar
Publikováno v:
Cancer Research. 83:P2-03
Background: Recent guidelines regarding estrogen (ER) and progesterone (PR) receptor testing from the American Society of Clinical Oncology and College of American Pathologists defined a new reporting category of ER-low positive breast cancer for tum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3dba93f30108cc298764fcada82f2672
https://doi.org/10.1158/1538-7445.sabcs22-p2-03-16
https://doi.org/10.1158/1538-7445.sabcs22-p2-03-16
Autor:
Jianxun Lei, Zhijun Guo, Julissa Molina-Vega, Paloma Cervantes, Swaathi Jayaraman, John R. Hawse, Carlos Perez, Juan Abrahante, Xiaojia Tang, Krishna Kalari, Jinhua Wang, John R. Falck, Carol Lange, Matthew P. Goetz, David Potter
Publikováno v:
Cancer Research. 82:LB564-LB564
While epoxyeicosatrienoic acids (EETs) have been implicated in breast cancer growth and progression, less is known about their effects on oncogene transcription. We have previously found that the oncogenic regioisomer (±)14,15-EET drives mitochondri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3c25f78a97d6e71ef066e59d9dedbbb2
https://doi.org/10.1158/1538-7445.am2022-lb564
https://doi.org/10.1158/1538-7445.am2022-lb564
Autor:
Dylan C. Castillejo Mijangos, Paloma Cervantes, Jinhua Wang, Zhijun Guo, Aline R. Rom'Mand, John R. Falck, Jianxun Lei, Carol A. Lange, Shaoping Wu, David Potter, Julissa Molina-Vega
Publikováno v:
Cancer Research. 80:4372-4372
Introduction: Cancer cell-intrinsic CYP monooxygenases promote tumor progression. In ER+HER2-, breast cancer cells, CYP3A4 promotes tumor growth, in part, through epoxyeicosatrienoic acid (EET) biosynthesis (1). The biguanide diabetes drug metformin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a9ce813891f2f1169b4a3319c16b205
https://doi.org/10.1158/1538-7445.am2020-4372
https://doi.org/10.1158/1538-7445.am2020-4372